Lenalidomide has immunomodulatory and anti-angiogenic effects and showed moderate anti-tumour efficacy in patients with. advanced hepatocellular carcinoma.
Dr Shao and colleagues explored potential biomarkers of lenalidomide efficacy as second-line therapy for hepatocellular carcinoma.
Eligible patients were diagnosed with advanced hepatocellular carcinoma, documented progression on sorafenib, and Child-Pugh class A liver function.
Patients received 25 mg/day lenalidomide orally on days 1-21 every 4 weeks.
The primary endpoint was 6 month progression-free survival rate.
Early α-fetoprotein response was defined as a larger than 20% decline of α-fetoprotein levels from baseline within the first 4 weeks of treatment.
Vascular response, evaluated using dynamic contrast-enhanced magnetic resonance imaging, was defined as a more than 40% decline in Ktrans after 2 weeks of treatment.
|The 6 month progression-free survival rate was 9%|
|Alimentary Pharmacology & Therapeutics|
The percentage of peripheral blood lymphocyte subsets were also analyzed.
The research team enrolled 55 patients.
The team found that the response rate was 13%, and the disease-control rate was 53%.
The 6 month progression-free survival rate was 9%.
The researchers observed that the median progression-free and overall survival was almost 2 months and 9 months respectively.
Early α-fetoprotein response was significantly associated with higher disease-control rate and longer progression-free survival.
Vascular response was not associated with any treatment outcomes.
Patients with a high pre-treatment B cell percentage were more likely to have disease control and exhibited longer progression-free survival.
Dr Shao's team concluded, "Lenalidomide exhibited moderate activity as second-line therapy for advanced hepatocellular carcinoma".
"Its immunomodulatory effects should be further explored".